[go: up one dir, main page]

NO996571L - Inhibitorer for farnesyl-protein-transferase - Google Patents

Inhibitorer for farnesyl-protein-transferase

Info

Publication number
NO996571L
NO996571L NO996571A NO996571A NO996571L NO 996571 L NO996571 L NO 996571L NO 996571 A NO996571 A NO 996571A NO 996571 A NO996571 A NO 996571A NO 996571 L NO996571 L NO 996571L
Authority
NO
Norway
Prior art keywords
inhibitors
protein transferase
farnesyl protein
farnesyl
transferase
Prior art date
Application number
NO996571A
Other languages
English (en)
Other versions
NO996571D0 (no
NO316117B1 (no
Inventor
Rajeev S Bhide
Charles Z Ding
John T Hunt
Soong-Hoon Kim
Katerina Leftheris
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO996571D0 publication Critical patent/NO996571D0/no
Publication of NO996571L publication Critical patent/NO996571L/no
Publication of NO316117B1 publication Critical patent/NO316117B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19996571A 1997-07-02 1999-12-30 Inhibitorer for farnesyl-protein-transferase, anvendelse av dem og farmasöytiske preparater inneholdende dem NO316117B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5159497P 1997-07-02 1997-07-02
PCT/US1998/012549 WO1999001434A1 (en) 1997-07-02 1998-06-16 Inhibitors of farnesyl protein transferase

Publications (3)

Publication Number Publication Date
NO996571D0 NO996571D0 (no) 1999-12-30
NO996571L true NO996571L (no) 2000-02-23
NO316117B1 NO316117B1 (no) 2003-12-15

Family

ID=21972255

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19996571A NO316117B1 (no) 1997-07-02 1999-12-30 Inhibitorer for farnesyl-protein-transferase, anvendelse av dem og farmasöytiske preparater inneholdende dem

Country Status (24)

Country Link
US (2) US6387926B1 (no)
EP (1) EP0994856A4 (no)
JP (1) JP2002507989A (no)
KR (1) KR100385941B1 (no)
CN (1) CN1261880A (no)
AR (1) AR016304A1 (no)
AU (1) AU734721B2 (no)
BR (1) BR9810465A (no)
CA (1) CA2294530A1 (no)
CO (1) CO4950556A1 (no)
HU (1) HUP0004148A3 (no)
ID (1) ID24076A (no)
IL (1) IL133470A0 (no)
MY (1) MY117961A (no)
NO (1) NO316117B1 (no)
NZ (1) NZ501293A (no)
PE (1) PE86599A1 (no)
PL (1) PL337697A1 (no)
RU (1) RU2211838C2 (no)
TR (1) TR199903331T2 (no)
TW (1) TW527355B (no)
UY (1) UY25074A1 (no)
WO (1) WO1999001434A1 (no)
ZA (1) ZA985778B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5196399A (en) * 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001047891A1 (en) * 1999-12-28 2001-07-05 Eisai Co., Ltd. Heterocyclic compounds having sulfonamide groups
GB0023915D0 (en) * 2000-09-29 2000-11-15 Inst Of Ophthalmology Treatment of neuroinflammatory disease
DK1339407T3 (da) * 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
FR2819510B1 (fr) * 2001-01-18 2003-10-31 Servier Lab Nouveaux composes cyclo[c] azepane, leur procede de preparation et les compositions pharmaceutiques qui le contiennent
FR2819512B1 (fr) * 2001-01-18 2003-02-21 Servier Lab Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US20040142888A1 (en) * 2002-08-07 2004-07-22 Veeraswamy Manne Modulators of RabGGT and methods of use thereof
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
EP1644335A4 (en) * 2003-07-11 2008-06-04 Bristol Myers Squibb Co TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
CA2546727C (en) 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
JP2009508809A (ja) 2005-07-29 2009-03-05 チルドレンズ ホスピタル メディカル センター ＲＡＣ−１ＧＴＰａｓｅのＧＴＰａｓｅ阻害因子とその使用方法およびその結晶構造
US8003624B2 (en) * 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
JP2009521470A (ja) * 2005-12-23 2009-06-04 リンク メディシン コーポレイション シヌクレイン障害の治療
BRPI0708685B8 (pt) * 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
CA2669112A1 (en) * 2006-11-16 2008-05-22 F. Hoffmann-La Roche Ag Substituted 4-imidazoles
US8987252B2 (en) * 2007-05-10 2015-03-24 Albany Molecular Research, Inc. Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2009079765A1 (en) * 2007-12-21 2009-07-02 Cascade Therapeutics Inc. Compounds with activity at the 5-ht2c receptor
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
NZ593090A (en) * 2008-11-13 2013-06-28 Link Medicine Corp Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
CN103864765B (zh) * 2014-03-05 2016-02-10 天津药物研究院 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP3452038B1 (en) 2016-05-05 2022-07-06 Laurus Labs Limited Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
WO2017213210A1 (ja) * 2016-06-10 2017-12-14 武田薬品工業株式会社 複素環化合物
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110536A (en) 1977-04-18 1978-08-29 Miles Laboratories, Inc. Derivatives of 5-(indol-3-yl)hydantoin
JPS5852256A (ja) * 1981-09-24 1983-03-28 Nippon Nohyaku Co Ltd 置換又は非置換脂肪酸アミド誘導体及びその塩類
JPS60222479A (ja) * 1984-04-20 1985-11-07 Nippon Tokushu Noyaku Seizo Kk テトラヒドロキノリン―１―イルカルボニルイミダゾール誘導体、その製法並びに除草又は農園芸用殺菌剤
US4576957A (en) 1984-07-05 1986-03-18 American Cyanamid Company N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas
JPS6160682A (ja) * 1984-08-30 1986-03-28 Nippon Tokushu Noyaku Seizo Kk テトラヒドロキノリン−１−イルカルボニルイミダゾ−ル誘導体、その中間体、それらの製法並びに除草又は農園芸用殺菌剤
JPS6168487A (ja) * 1984-09-12 1986-04-08 Sumitomo Chem Co Ltd カルバモイルアゾール誘導体およびそれを有効成分とする除草剤
US5017584A (en) 1984-12-20 1991-05-21 Sterling Drug Inc. Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
JPS61227506A (ja) * 1985-04-01 1986-10-09 Nippon Tokushu Noyaku Seizo Kk カルバモイルイミダゾ−ル類、その中間体、それらの製法並びに除草剤又は農園芸用殺菌剤
JPS61280408A (ja) * 1985-06-03 1986-12-11 Sumitomo Chem Co Ltd たばこ腋芽抑制剤
JPS63270678A (ja) * 1987-04-30 1988-11-08 Mitsui Petrochem Ind Ltd 新規含窒素化合物
JP2652249B2 (ja) 1989-08-22 1997-09-10 進 根本 キーのつまみ部カバー
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
EP0485890A3 (en) * 1990-11-16 1992-07-08 Hoechst Aktiengesellschaft Use of 2,3-disubstituate 1-azolyl-propane for inhibiting the pathogenic growth phase of dimorph yeast cell
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5371227A (en) 1991-10-28 1994-12-06 Synthelabo Quinoline derivatives, process for their preparation, and their therapeutic applications
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
IT1255704B (it) * 1992-09-30 1995-11-10 Boehringer Mannheim Italia Ammine eterocicliche utili nella terapia dell'asma e dell'infiammazione delle vie aeree
US5726197A (en) 1992-11-02 1998-03-10 Syntex (U.S.A.) Inc. Isoindolinyl derivatives
US5284841A (en) 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5523317A (en) 1993-07-05 1996-06-04 Nippon Chemiphar Co., Ltd. Method of reducing blood pressure
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
DE69424183T2 (de) 1993-12-17 2001-02-15 The Procter & Gamble Company, Cincinnati 6-(2-imidazolinylamino)chinolin-verbindungen als alpha-2-adrenoceptor-antagonisten
RU95104898A (ru) * 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
US5607939A (en) 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
RU2076864C1 (ru) * 1995-07-31 1997-04-10 Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН Гидрохлориды серосодержащих 2-аминоимидазолов или 2-аминотиазолов, обладающие цитотоксической и противоопухолевой активностью и проявляющие ингибирующее действие в отношении некоторых ферментов
TW436484B (en) 1996-04-24 2001-05-28 Dev Center Biotechnology 1,2,3,4-tetrahydroisoquinoline derivatives having a nitrogen-containing heterocyclic methyl substituent, the preparation process and pharmaceutical composition thereof
AU3460797A (en) 1996-07-16 1998-02-09 Takeda Chemical Industries Ltd. Bicyclic compounds for controlling micturition
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
IL133470A0 (en) 2001-04-30
NO996571D0 (no) 1999-12-30
US6387926B1 (en) 2002-05-14
US6602883B1 (en) 2003-08-05
TW527355B (en) 2003-04-11
WO1999001434A1 (en) 1999-01-14
TR199903331T2 (xx) 2000-06-21
AR016304A1 (es) 2001-07-04
NZ501293A (en) 2001-10-26
MY117961A (en) 2004-08-30
ID24076A (id) 2000-07-06
KR20010014258A (ko) 2001-02-26
ZA985778B (en) 2000-01-20
CA2294530A1 (en) 1999-01-14
PE86599A1 (es) 1999-11-28
EP0994856A4 (en) 2000-12-06
PL337697A1 (en) 2000-08-28
NO316117B1 (no) 2003-12-15
CN1261880A (zh) 2000-08-02
CO4950556A1 (es) 2000-09-01
EP0994856A1 (en) 2000-04-26
AU7971998A (en) 1999-01-25
AU734721B2 (en) 2001-06-21
HUP0004148A3 (en) 2002-09-30
RU2211838C2 (ru) 2003-09-10
HUP0004148A2 (hu) 2001-10-28
UY25074A1 (es) 2000-12-29
BR9810465A (pt) 2002-04-16
KR100385941B1 (ko) 2003-06-09
JP2002507989A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
NO996571L (no) Inhibitorer for farnesyl-protein-transferase
EE04309B1 (et) Farnesüül-proteiini transferaasi inhibiitorid
EE9800408A (et) Proteiinfarnesüültransferaasi inhibiitorid
NO974457D0 (no) Inhibitorer for farnesylproteintransferase
EP0944388A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP1011669A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0891350A4 (en) INHIBIOTS OF FARNESYL PROTEIN TRANSFERASE
FI951554A0 (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
DE69924876D1 (de) Farnesyl protein transferase inhibitoren
EP0841919A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
NO951647D0 (no) Inhibitorer for farnesylproteintransferase
EP0891360A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ATE546139T1 (de) Isoprentransferase proteine inhibitoren
EP0777475A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
FI952011L (fi) Farnesyyliproteiinitransferaasin estäjät
EP0784473A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0904080A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP1027042A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0783305A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP0812203A4 (en) INHIBITORS OF GERANYLGERANYL PROTEIN TRANSFERASE
ATE214367T1 (de) Farnesyl transferase inhibitoren
EP0891352A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP1035850A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
EP1035852A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0891353A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS